We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




HbA1c Measurements Predict Heart Disease in Diabetics

By LabMedica International staff writers
Posted on 10 Aug 2011
Print article
The measurement of hemoglobin 1Ac (Hb1Ac) in patients with diabetes improves the prediction of cardiovascular disease (CVD) events occurring.

The glycosalated HbA1c test reflects the average blood glucose level over the previous 8 to 13 weeks and is generally viewed as an indicator on how well the patient is managing or controlling their diabetes.

A team of scientists at Brigham and Women's Hospital (Boston, MA, USA) set out to determine how useful monitoring HbA1c levels might be in predicting cardiovascular events. They gathered data from 24,674 females, of whom 685 had had diabetes at baseline, while out of 11,280 males 563 had diabetes at baseline. Baseline blood samples were evaluated for HbA1c, C-reactive protein, and cholesterol levels. The females were followed up for new CVD incidents for an average of 10.2 years, and the males for 11.8 years.

The results of the study showed that within the female cohort, there were 125 cardiovascular events out of 685 diabetic participants, compared to 665 out of 24,674 without diabetes. For the male diabetic cohort there were 170 cardiovascular events out of 563 participants, compared to 1,382 out of 11,280 without diabetes. The scientists noted that including HbA1c modeling for CVD improved CVD prediction compared to the general prediction of all high-risk diabetes participants. This was especially the case among females. The risk modeling showed that 71.9% of women with diabetes in this study had a less than 20% risk of CVD over a ten-year period, compared to just 24.5% of their male counterparts.

The study concluded that in these large population-based cohorts of both men and women, presence of diabetes alone did not confer a 10-year risk of CVD higher than 20%, and measurement of HbA1c level in diabetic subjects improved risk prediction compared with classification as cardiovascular risk equivalent. The study was published on July 25, 2011, in the Archives of Internal Medicine.

Related Links:
Brigham and Women's Hospital



Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
ACTH Assay
ACTH ELISA
New
Multi-Function Pipetting Platform
apricot PP5

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.